RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q4 2020
Top Holdings82 positions
ASCENDIS PHARMA A/S | 5.9M | $978.2M | 13.7% | $83.05 | +104.93% | 9 qtrssince 2018-Q4 | Decreased 0 |
TG Therapeutics Inc | 8.7M | $451.8M | 6.3% | $8.58 | +516.13% | 9 qtrssince 2018-Q4 | Decreased 0 |
NOVAVAX INC COM NEW | 3.8M | $422.5M | 5.9% | $107.78 | +10.38% | 3 qtrssince 2020-Q2 | Increased 98 |
NKARTA INC COM | 5.6M | $344.5M | 4.8% | $30.36 | +116.37% | 2 qtrssince 2020-Q3 | Unchanged 0 |
FORMA THERAPEUTICS HLDGS INC | 9M | $314.5M | 4.4% | — | — | 3 qtrssince 2020-Q2 | Unchanged 0 |
ARVINAS INC COM | 3.7M | $311.9M | 4.4% | $29.09 | +183.70% | 9 qtrssince 2018-Q4 | Unchanged 0 |
| 4.8M | $295.8M | 4.1% | — | — | 5 qtrssince 2019-Q4 | Decreased 0 | |
ATEA PHARMACEUTICALS INC COM | 5.4M | $224.3M | 3.1% | $41.71 | 0.00% | 1 qtr | New 85 |
ITEOS THERAPEUTICS INC | 4.4M | $149.4M | 2.1% | — | — | 2 qtrssince 2020-Q3 | Unchanged 0 |
KINNATE BIOPHARMA INC | 3.6M | $142.9M | 2.0% | — | — | 1 qtr | New 69 |
AXSOME THERAPEUTICS INC | 1.7M | $134.9M | 1.9% | $50.95 | +63.40% | 8 qtrssince 2019-Q1 | Decreased 0 |
KEROS THERAPEUTICS INC COM | 1.9M | $132.3M | 1.8% | $38.00 | -68.55% | 3 qtrssince 2020-Q2 | Unchanged 0 |
PHATHOM PHARMACEUTICALS INC | 3.8M | $127.1M | 1.8% | $32.43 | +3.86% | 5 qtrssince 2019-Q4 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 4.2M | $124.2M | 1.7% | $23.93 | +24.22% | 9 qtrssince 2018-Q4 | Decreased 0 |
TRAVERE THERAPEUTICS INC COM | 4.6M | $124.2M | 1.7% | $27.26 | 0.00% | 1 qtr | New 69 |
IMMUNOGEN INC | 18.4M | $118.8M | 1.7% | — | — | 2 qtrssince 2020-Q3 | Increased 77 |
ROCKET PHARMACEUTICALS INC | 2.1M | $117.1M | 1.6% | $56.05 | 0.00% | 1 qtr | New 69 |
89BIO INC | 4.7M | $115.4M | 1.6% | — | — | 5 qtrssince 2019-Q4 | Unchanged 0 |
ZOGENIX INC | 5.3M | $106.9M | 1.5% | — | — | 9 qtrssince 2018-Q4 | Decreased 0 |
PMV PHARMACEUTICALS INC | 1.7M | $105.2M | 1.5% | $38.00 | +48.50% | 2 qtrssince 2020-Q3 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $7.2B across 82 positions as of Q4 2020. Top holdings: ASND (13.7%), TGTX (6.3%), NVAX (5.9%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.
Active quarter - 23 new positions, 11 exits, 4 increased. Top move: NVAX (INCREASED, conviction 98). Portfolio: $7.2B across 82 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR